| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers C > Headlines for Celsion Corp. > News item |
Celsion treats three patients in ThermoDox liver cancer trial in Hong Kong
By Elaine Rigoli
Tampa, Fla., May 9 - Celsion Corp. said Queen Mary Hospital, an affiliate of the University of Hong Kong, has begun to participate as an additional site in Celsion's ongoing phase 1 dose-escalation study investigating the use of ThermoDox in combination with radiofrequency ablation to treat liver cancer.
The first three patients have been successfully treated at the center. This brings the total of treated patients in the study to 14, counting the patients at the current site in the National Cancer Institute located in Bethesda, Md., according to a news release.
The company also announced treatment of the first patient in a phase 1, dose-escalation, multi-dose study of the safety and pharmacokinetics of ThermoDox in combination with microwave heat to treat patients with local regionally advanced recurrent breast cancer.
Microwave heat is being provided by the use of a BSD 500 device. Local-regionally recurrent breast cancer is a condition that occurs in post mastectomy patients where lesions recur on the chest wall. There is no established standard of care for this condition, according to the release.
Celsion further announced that under its direction, a contract manufacturing facility has completed the production of the first full scale GMP batch of ThermoDox using a process and formulation design suitable for commercial introduction, which consists of a single ready for use vial, which requires no complex pre-mixing process prior to use as an infusion.
Celsion, based in Columbia, Md., is a biotechnology company that develops heat-activated treatment systems for cancer.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.